Expanding drug-trafficking enforcement to counterfeit pharmaceuticals and substandard ingredients.
S. 3134 — Combating Counterfeit Pharmaceuticals Act of 2025 · Filed by Tom Cotton (R-AR) · 1 cosponsor · Introduced Nov 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Fentanyl Sanctions Act to expand its scope beyond fentanyl to cover counterfeit drugs and 'copy-cat' pharmaceutical ingredients—substances designed to mimic approved drugs but made with inferior processes or lower purity. It allows the Director of National Intelligence to delegate authority to subordinates, adds a waiver permitting access to sanctioned medications during drug shortages, and makes conforming changes throughout the statute to reflect the broader focus on illicit drugs generally.
Why we flagged it
The bill's operative mechanism is to broaden existing sanctions authority from fentanyl-specific to all illicit drugs and counterfeit pharmaceuticals, adding definitional clarity and administrative delegation. It is a straightforward law-enforcement tool, not a market intervention or private carve-out.
What the text implies
- The 'copy-cat ingredient' definition may capture legitimate generic pharmaceutical manufacturing if the process differs from the original approval, creating potential enforcement ambiguity and compliance burden for generic manufacturers.
- The drug shortage waiver (Section 4) creates a narrow exception to sanctions but does not establish clear criteria for what constitutes a 'current drug shortage'—implementation will depend on HHS list maintenance and may leave gaps during supply disruptions.
- Delegation to DNI designees (Section 3) decentralizes identification and briefing authority, potentially accelerating sanctions decisions but reducing direct congressional oversight of individual designations.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill expands law-enforcement tools against counterfeit and substandard pharmaceuticals that pose direct health risks to consumers, while adding a safety valve (drug shortage waiver) to prevent sanctions from blocking access to needed medications. The delegation provision is routine administrative efficiency.
Named in the bill
Director of National Intelligence, Department of Health and Human Services, Fentanyl Sanctions Act, Federal Food, Drug, and Cosmetic Act, Public Health Service Act, Foreign Assistance Act of 1961
Where it stands
1 cosponsor: 1 Republicans.
- Nov 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Nov 6, 2025 — Referred to Senate Committee on Banking, Housing, and Urban Affairs · Congress.gov: “Read twice and referred to the Committee on Banking, Housing, and Urban Affairs”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,411 characters) on Aug 17, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Expanding drug-trafficking enforcement to counterfeit pharmaceuticals and substandard ingredients.” QuorumCivic. https://share.quorumcivic.app/bill/119/s3134 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.